药物研发：机遇之窗。 - Suppr | 超能文献

相似文献

1

Drug discovery: Pocket of opportunity.药物研发：机遇之窗。

Nature. 2013 Nov 28;503(7477):475-6. doi: 10.1038/nature12835. Epub 2013 Nov 20.

2

Oncogenes: direct hit on mutant RAS.癌基因：直接作用于突变型RAS

Nat Rev Cancer. 2014 Jan;14(1):8-9. doi: 10.1038/nrc3650. Epub 2013 Dec 5.

3

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.K-Ras(G12C) 抑制剂变构控制 GTP 亲和力和效应物相互作用。

Nature. 2013 Nov 28;503(7477):548-51. doi: 10.1038/nature12796. Epub 2013 Nov 20.

4

GTP-GDP exchange proteins.鸟苷三磷酸-鸟苷二磷酸交换蛋白

Science. 1990 May 18;248(4957):794. doi: 10.1126/science.2188357.

5

Kinetics of interaction of nucleotides with nucleotide-free H-ras p21.核苷酸与无核苷酸的H-ras p21相互作用的动力学

Biochemistry. 1990 Jun 26;29(25):6058-65. doi: 10.1021/bi00477a025.

6

Purification and characterization from bovine brain cytosol of proteins that regulate the GDP/GTP exchange reaction of smg p21s, ras p21-like GTP-binding proteins.从牛脑胞质溶胶中纯化和鉴定调节smg p21s（一种ras p21样GTP结合蛋白）的GDP/GTP交换反应的蛋白质。

J Biol Chem. 1990 Sep 25;265(27):16626-34.

7

[ras p21/ras p21-like small G proteins and their regulatory proteins].[Ras p21/Ras p21样小G蛋白及其调节蛋白]

Nihon Rinsho. 1990 Aug;48(8):61-70.

8

Conformational effects of nucleotide exchange in ras p21 proteins as studied by fluorescence spectroscopy.通过荧光光谱法研究ras p21蛋白中核苷酸交换的构象效应。

FEBS Lett. 1990 Mar 12;262(1):127-30. doi: 10.1016/0014-5793(90)80170-n.

9

Comparison of the low energy conformations of an oncogenic and a non-oncogenic p21 protein, neither of which binds GTP or GDP.一种致癌性和一种非致癌性p21蛋白的低能量构象比较，这两种蛋白均不结合GTP或GDP。

J Protein Chem. 1994 Feb;13(2):237-51. doi: 10.1007/BF01891982.

10

Inhibition of SDC25 C-domain-induced guanine-nucleotide exchange by guanine ring binding domain mutants of v-H-ras.v-H-ras的鸟嘌呤环结合结构域突变体对SDC25 C结构域诱导的鸟嘌呤核苷酸交换的抑制作用。

J Biol Chem. 1993 Nov 25;268(33):24692-8.

引用本文的文献

1

AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis.AIMP2-DX2 提供治疗性接口以控制 KRAS 驱动的肿瘤发生。

Nat Commun. 2022 May 11;13(1):2572. doi: 10.1038/s41467-022-30149-2.

2

Pancreatic adenocarcinoma: A review of recent paradigms and advances in epidemiology, clinical diagnosis and management.胰腺导管腺癌：流行病学、临床诊断和治疗的最新模式和进展综述。

World J Gastroenterol. 2021 Jun 21;27(23):3158-3181. doi: 10.3748/wjg.v27.i23.3158.

3

Inhibition of RAS: proven and potential vulnerabilities.RAS 抑制：已证实和潜在的弱点。

本文引用的文献

1

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.K-Ras(G12C) 抑制剂变构控制 GTP 亲和力和效应物相互作用。

Nature. 2013 Nov 28;503(7477):548-51. doi: 10.1038/nature12796. Epub 2013 Nov 20.

2

US National Cancer Institute's new Ras project targets an old foe.美国国家癌症研究所的新Ras项目将目标对准了一个老对手。

Nat Med. 2013 Aug;19(8):949-50. doi: 10.1038/nm0813-949.

3

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.